Covers three separate trials testing JAK inhibitor drugs (abrocitinib, baricitinib, upadacitinib) for immune dysregulation believed to underlie some Long COVID symptoms, ranging from phase 2 to phase 3 in design. Notes patient experiences with these drugs so far have been mixed.
Treatment & Management
Three Clinical Trials for Long COVID Are Testing JAK Inhibitors to Treat Immune Dysregulation
August 5, 2025
Three trials are testing JAK inhibitor drugs for immune dysregulation believed to underlie some Long COVID symptoms, with mixed patient experiences so far.
Save For Later
Email yourself a link to this article.
Saved. Check your email app.
Something didn't go through — try again.